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Abstract
Interest in RNA dysfunction in amyotrophic lateral sclerosis (ALS)
recently aroused upon discovering causative mutations in RNA-
binding protein genes. Here, we show that extensive down-
regulation of miRNA levels is a common molecular denominator
for multiple forms of human ALS. We further demonstrate that
pathogenic ALS-causing mutations are sufficient to inhibit miRNA
biogenesis at the Dicing step. Abnormalities of the stress response
are involved in the pathogenesis of neurodegeneration, including
ALS. Accordingly, we describe a novel mechanism for modulating
microRNA biogenesis under stress, involving stress granule forma-
tion and re-organization of DICER and AGO2 protein interactions
with their partners. In line with this observation, enhancing DICER
activity by a small molecule, enoxacin, is beneficial for neuromus-
cular function in two independent ALS mouse models. Characteriz-
ing miRNA biogenesis downstream of the stress response ties
seemingly disparate pathways in neurodegeneration and further
suggests that DICER and miRNAs affect neuronal integrity and are
possible therapeutic targets.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease
of the human motor neuron system. Mutations in genes encoding
RNA-binding proteins were recently identified as causative in
human ALS. These include TAR DNA-binding protein 43 (TDP-43)
(Kabashi et al, 2008; Sreedharan et al, 2008; Liu-Yesucevitz et al,
2010; McDonald et al, 2011), fused in sarcoma (FUS) (Kwiatkowski
et al, 2009; Vance et al, 2009; Bosco et al, 2010; Gal et al, 2010)
and heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) (Kim
et al, 2013).
Stress granules (SGs) are cytoplasmic sites for modulating mRNA
translation and form in response to cellular stress (Anderson &
Kedersha, 2008, 2009; Buchan & Parker, 2009). Intriguingly, among
the RNA-binding proteins that are recruited into SGs, several are
mutated in ALS or the related disorder fronto-temporal dementia
(FTD), for example, TDP-43 and FUS.
Stress and SGs are thought to be involved in the pathogenesis of
ALS, and SGs are observed in pathologic ALS/FTD specimen
(Neumann et al, 2007; Volkening et al, 2009; Bosco et al, 2010;
Dormann et al, 2010; Gal et al, 2010; Liu-Yesucevitz et al, 2010;
Dewey et al, 2011; McDonald et al, 2011; Meyerowitz et al, 2011;
Aulas et al, 2012; Baron et al, 2013; Daigle et al, 2013; Kim et al,
2013; Vance et al, 2013; reviewed in Dewey et al, 2012; Emde &
Hornstein, 2014; Li et al, 2013b; Ling et al, 2013). SG formation is
initiated by the phosphorylation of eukaryotic translation initiation
factor 2 alpha (EIF2A) on serine-51 or by the expression of several
aggregation-prone proteins that are capable of initiating SG
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nucleation (Kedersha et al, 1999). Accordingly, modulation of
EIF2A phosphorylation mitigates neurotoxicity in animal models of
ALS (Saxena et al, 2009; Kim et al, 2014).
microRNAs (miRNAs) are small endogenous RNAs. Initial
processing of primary miRNAs by Drosha/Dgcr8 (Gregory et al,
2004) yields an intermediate pre-miRNA that is further processed by
the 500-kDa DICER multi-protein complex to form a mature
miRNA. This complex contains DICER 1, ribonuclease type III
(DICER) and its partners, Argonaute RISC catalytic component 2
(AGO2), TAR (HIV-1) RNA-binding protein 2 (also known as TRBP)
and protein kinase, interferon-inducible double-stranded RNA-
dependent activator (PACT) (Chendrimada et al, 2005; Haase et al,
2005; Lee et al, 2006). DICER activity is controlled by its core
partners (Ma et al, 2008; Shan et al, 2008; Li et al, 2012; Lee et al,
2013) and the mature miRNA is loaded onto AGO2, creating a func-
tional RNA-induced silencing complex (RISC).
DICER and its co-factors participate at multiple levels of the
stress response (Emde & Hornstein, 2014). Thus, DICER contributes
to stress resistance in selected tissues and its deficiency reduces
stress tolerance (Mori et al, 2012). In addition, various stress-
signaling cascades control AGO2 post-translational modifications,
its translocation into SGs and its activity (Leung et al, 2006; Qi et al,
2008; Zeng et al, 2008; Shen et al, 2013).
We previously demonstrated that loss of miRNA biogenesis is
sufficient to cause spinal motor neuron degeneration in vivo
(Haramati et al, 2010). In the current work, we demonstrate that
reduction in miRNA levels is a common molecular denominator for
multiple forms of familial and sporadic human ALS and that
enhancement of DICER activity is beneficial in vivo in two indepen-
dent ALS mouse models. The observations establish a novel path-
way downstream of the stress response that controls DICER
complex activity. The regulation of DICER involves stress granule
assembly and dynamic interactions with SG proteins. This new
mechanism for the control of miRNA biogenesis offers novel thera-
peutic targets for ALS.
Results
miRNAs are down-regulated in motor neurons of human
ALS patients
We recently demonstrated that conditional inactivation of DICER in
motor neurons is sufficient to cause spinal motor neuron degenera-
tion in vivo (Haramati et al, 2010). Additional works from other
groups further suggest the involvement of miRNAs in ALS patho-
genesis (Williams et al, 2009; Buratti et al, 2010; Kawahara &
Mieda-Sato, 2012; Morlando et al, 2012; Droppelmann et al, 2013;
Freischmidt et al, 2013; Koval et al, 2013; Zhang et al, 2013). To
pursue this, we examined miRNA expression in lumbar motor
neurons of sporadic ALS (sALS) spinal cords isolated by laser
capture microdissection (LCM). Global down-regulation of miRNAs
was observed in motor neurons. The observation seemed specific to
motor neurons since RNA extracted from surrounding, motor
neuron-depleted ventral-horn tissue of sALS patients or from
neurons of Clarke’s column (non-motor neuron) isolated by LCM
within the same nervous systems did not exhibit such global
changes in miRNA expression (Fig 1A–C). The observations of
miRNA down-regulation were substantiated by miRNA in situ
hybridization, which revealed down-regulation of miR-9 and
miR-124 in patient tissue, relative to control tissue and to the
hybridization signal of U6 RNA (Fig 1D). We next investigated
whether miRNAs display a similar profile in fALS cases. Indeed,
analyzing two nervous systems carrying familial SOD1 A4V muta-
tion, revealed similar down-regulation of miRNAs (Fig 1E and F)
that correlated with miRNA changes, observed in sALS (Pearson’s
correlation coefficient = 0.3). Our data suggest that changes in
miRNA expression, which were previously reported in ALS spinal
cord extracts (Campos-Melo et al, 2013), are primarily due to
changes in miRNA expression in motor neurons. Attempts to
measure pre-miRNAs in human LCM samples were unsuccessful,
probably due to the low abundance of these intermediate precur-
sors. Noteworthy, expression and splicing data for changes in
mRNAs encoding miRNA biogenesis factors from the relevant ALS
patients did not reveal any change, relative to controls (Rabin et al,
2009). Additionally, 27 long ncRNAs tested were similarly
expressed in another cohort of 12 non-ALS and 12 sporadic ALS
nervous systems, with Pearson’s correlation of 0.9882. Since
miRNAs are globally down-regulated in sALS cases that are geneti-
cally unrelated, reduced miRNA expression in motor neurons
appears to be a common denominator of various forms of ALS.
Cellular stress affects pre-miRNA processing
Stress pathways are thought to control miRNA activity (Leung &
Sharp, 2010; Mendell & Olson, 2012; Emde & Hornstein, 2014),
but the idea that cellular stress might broadly regulate miRNA
biogenesis has not been tested. We sought to do so by the
measurement of the relative levels of mature miRNAs and pre-
miRNAs under several stress conditions. We further defined an
“inhibition score” that approximates a value of one, when DICER
processes pre-miRNAs effectively, as in wild-type conditions, and
increases >1, when miRNA biogenesis is inhibited, relative to
control (Fig 2A).
We chose representative miRNAs that are expressed in human
and mouse motor neurons including miR-10b, miR-30a and miR-103
(abundantly expressed in isolated mouse motor neurons); miR-218,
miR-30c, miR-138 and let-7b (highly expressed in human motor
neurons); miR-132, let-7c and let-7d (neuronal, mid-range in human);
and miR-143 and let-7a (low expression in human neurons).
We triggered cellular stress in the hybrid motor neuron cell line
NSC-34; using thapsigargin induced markers of ER stress (Appendix
Fig S1A), down-regulated mature miRNA levels and up-regulated
pre-miRNA levels, relative to control, demonstrating the inhibition
of miRNA biogenesis (Fig 2B–D). In addition, application of oxida-
tive stressors, paraquat or sodium arsenite, led to the inhibition of
miRNA biogenesis (Fig 2E–J, Appendix Fig S1B).
To test whether changes in DICER or its co-factors are down-
regulated as a result of stress, we measured protein levels by
Western blot analysis. The expression levels of the four DICER
complex proteins were not down-regulated by two independent
stressors (thapsigargin, paraquat). DICER and AGO2 levels were not
reduced by sodium arsenite as well, but PACT and TRBP levels were
reduced by 1/3 (Appendix Fig S2 related to Fig 2). We conclude that
alteration of DICER activity may occur even without reduction in
DICER complex components.
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Expression of ALS-causing genes inhibits pre-miRNA processing
To assess whether ALS-causing genes affect miRNA biogenesis
similar to chemical stressors, we transfected NSC-34 cells with
vectors of wild-type FUS, TDP-43 and SOD1 or mutant forms of
the same genes, specifically FUS R495X (Bosco et al, 2010;
Waibel et al, 2010), TDP-43 A315T (Gitcho et al, 2008) and
SOD1 G93A (Rosen et al, 1993) (Fig 3A). We observed inhibition
in biogenesis of many of the miRNA species tested, relative to
the corresponding control sample values, after overexpression of
wild-type or mutant FUS and TDP-43 (Fig 3B–E, Appendix Fig S3).
The inhibitory effect of wild-type SOD1 or G93A mutant on
miRNA biogenesis was consistent with this, but more limited (Fig 3F





Figure 1. miRNAs are down-regulated in human ALS motor neurons.
A–C Volcano plots of P-values (y-axis log10 scale) for relative miRNA expression (x-axis log2 scale). (A) Human lumbar motor neurons (eight sporadic ALS nervous
systems, nine non-neurodegeneration controls), (B) anterior horn tissue without motor neurons from the same individuals (10 sporadic ALS nervous systems, nine
controls) and (C) miRNA expression in Clarke’s column (three sporadic ALS nervous systems versus three controls).
D Representative micrographs with in situ hybridization for miR-9 and miR-124; scale bar indicates 10 lM. Bar graph displays signal intensity, quantified in 300
different motor neurons of two ALS nervous systems and two controls, normalized to U6 in situ hybridization signal. Error bars represent s.d.
E, F miRNA expression in lumbar motor neurons of two familial ALS nervous systems versus nine controls (E) and the respective anterior horn tissue depleted of motor
neurons (F). Analyses were performed as in (A–C).
Data information: (A–C, E, F) Black dots indicate P < 0.05; light gray dots are non-significant. miRNAs were measured using TaqMan array microRNA cards,
normalized to the average of three control RNAs: RNU48/SNORD48, RNU44/SNORD44 and U6 and subjected to ANOVA Statistics (DataAssist, Life Technologies).
Source data are available online for this figure.
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wild-type FUS, TDP-43 or SOD1 is in accordance with the previous
reports (Jaarsma et al, 2000; Wils et al, 2010; Igaz et al, 2011;
Mitchell et al, 2013). Western blot analysis revealed that the levels
of DICER, AGO2, PACT and TRBP did not change by the overexpres-





































































































































































































































































































































































































































































Figure 2. Different cellular stressors lead to impaired miRNA biogenesis.
A Diagram depicting the working hypothesis. The DICER complex is composed of DICER, AGO2, PACT and TRBP, and the catalysis of pre-miRNA hairpins into mature
AGO2-loaded miRNAs is schematically presented by a vertical arrow. Stress inhibits Dicing, resulting in the accumulation of substrate (pre-miRNA) and reduction in
product levels (mature miRNA). The ratio of substrate to product, defined as “inhibition score,” approximates a value of 1 in the unmanipulated wild-type
conditions. Inhibition score values greater than 1, reflect reduced DICER activity.
B–J Pre-miRNA (B, E, H) and miRNA (C, F, I) expression analysis and their corresponding inhibition score (D, G, J). NSC-34 cells treated with thapsigargin (10 nM for
24 h) or control carrier (DMSO) (B–D), paraquat (25 lM for 24 h) or control carrier (water) (E–G) and sodium arsenite (0.5 mM for 60 min) or control carrier (water)
(H–J). Displayed are average and standard error of the mean (s.e.m.) for qPCR analyses of at least three independent experiments, normalized to the expression
levels in control treatments. Pre-miRNA levels were normalized to beta-actin and Gapdh, and miRNAs were normalized to Snord68 and Snord70. P-values of qPCR
were calculated via ANOVA statistics with DataAssist, and with two-sided Student’s t-test for inhibition score. Significant P-values are indicated by *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001.
Source data are available online for this figure.
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In order to test DICER activity directly, we devised a cell-free
Dicing assay, using cell lysates and synthetic double-stranded RNA,
carrying a quencher on a 25-nt passenger strand and a CY3 fluoro-
phore conjugate on a 27-nt precursor guide strand. Dicing activity
enables the dissociation of a fluorophore conjugate RNA from the
quencher and fluorescence (Fig 4A). The assay demonstrated
reduction in DICER catalytic activity in lysates of cells treated with
sodium arsenite, paraquat or thapsigargin (Fig 4B and C). Impor-
tantly, overexpression of ALS-causing mutants or their respective
wild-type forms also reduced DICER activity (Fig 4D). Noteworthy is
that the in vitro assay probably provides an underestimate of the













































































































































































































































































































































Figure 3. Over-expression of ALS-causing mutant proteins leads to impaired miRNA biogenesis.
A Diagram depicting the working hypothesis that expression of ALS-causing TDP-43, FUS or SOD1 attenuates DICER complex activity directly, or through induction of
stress.
B–G Inhibition score of FUS R495X (B), wild-type FUS (C), TDP-43 A315T (D), wild-type TDP-43 (E), SOD1 G93A (F) or wild-type SOD1 (G). The calculated values are based on
qPCR analysis results of pre-miRNAs, mature miRNAs of NSC-34 cell RNA, 72 h post-transfection, which is presented in Appendix Fig S3. The inhibition score of
individual pre-miRNA:miRNA pairs was normalized to values in cells transfected with control vector. Shown are average and s.e.m. of > 3 independent experiments,
except for pre-miRNAs in the study of FUS R495X (n = 2). P-values were calculated by two-sided Student’s t-test, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Source data are available online for this figure.
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Figure 4. Stress or over-expression of ALS-causing mutants inhibits DICER activity in cell lysates.
A Diagram of the in vitro DICER activity assay, in which an annealed double-stranded RNA substrate is composed of a fluorophore-conjugated 27-nt guide strand
and a 25-nt passenger strand conjugated to a quencher moiety. The DICER complex releases a 21-nt mature single-stranded guide RNA, whose fluorescence
correlates with DICER activity.
B, C Dicing in vitro assay was performed in NSC-34 lysates after treatment with (B) sodium arsenite (0.5 mM for 60 min), paraquat (25 lM for 24 h) or control carrier
(water), or alternatively (C) with thapsigargin (10 nM for 24 h) versus control carrier DMSO.
D Dicing in vitro assay was performed in HEK293 cell extracts 72 h post-transfection with the indicated plasmids.
E–G Inhibition score of DICER activity in cells transfected with ALS-causing mutants FUS R495X (E), TDP-43 A315T (F) or SOD1 G93A (G) and treated with carrier (buffer)
or enoxacin (100 lM) for 72 h. The calculated values are based on qPCR analysis of pre-miRNAs, and mature miRNAs of NSC-34 cell RNA that is presented in
Appendix Fig S5. Inhibition score of individual pre-miRNA:miRNA pairs was normalized to values in cells transfected with control vector.
Data information: (B–G) Shown are average and s.e.m. of > 3 independent experiments. P-values were calculated by two-sided Student’s t-test, *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001.
Source data are available online for this figure.
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DICER cofactors in the reaction buffers. Therefore, overexpression
of ALS genes, mutation in ALS genes and the application of oxida-
tive or ER stress all inhibit DICER catalytic activity.
Enoxacin ameliorates ALS-induced defects in
pre-miRNA processing
Next, we hypothesized that enhancing Dicing complex activity
might reverse the negative effect of the ALS-causing mutant proteins
on miRNA processing. We tested this hypothesis by employing
enoxacin, a fluoroquinolone antibiotic that is commonly used for
the treatment of urinary tract and airway infections. Enoxacin is
known to increase miRNA biogenesis via increasing the binding
affinity of TRBP and pre-miRNAs (Shan et al, 2008; Melo et al,
2011). Intriguingly, the impairments in pre-miRNA processing that
were evident in NSC-34 cells upon transfection with vectors express-
ing ALS-causing mutants FUS R495X, TDP-43 A315T or SOD1 G93A
were partially ameliorated by applying enoxacin (100 lM for 72 h)
to transfected cultures (Fig 4E–G and Appendix Fig S5). Therefore,
enoxacin studies further support the view that DICER activity is
impaired in culture models of ALS.
Stress granule formation controls miRNA biogenesis
To gain further mechanistic insight, we performed targeted mass
spectrometry analysis of AGO2 and DICER protein interactions
under cellular stress (Fig 5A). We examined a set of proteins that
were co-immunoprecipitated with either AGO2 or DICER in a
preliminary unbiased screen. Targeted mass spectrometry revealed
enhanced interactions of AGO2 with DICER in cells that were treated
with sodium arsenite, relative to basal conditions (Fig 5B and C).
We report increased AGO2 binding to DICER, which was previously
shown to decrease DICER complex activity (Tahbaz et al, 2004).
As DICER complex composition controls miRNA biogenesis (Lee
& Doudna, 2012; Lee et al, 2013), we measured additional AGO2 and
DICER interactions. HSP90 and co-chaperone p23, which regulate
the interactions of DICER with AGO2 (Tahbaz et al, 2004; Pare et al,
2013), increased their interactions with DICER under stress (Fig 5B).
These interactions potentially stabilize an intermediate DICER–
AGO2–P23–HSP90 complex (Pare et al, 2013), thereby inhibiting
DICER catalytic activity. In addition, cellular stress increased AGO2
and/or DICER protein interactions with SG components EIF2A,
EIF3 (Kedersha et al, 2005) and EIF5A (Li et al, 2010) and with
poly(rC)-binding proteins PCBP1 (hnRNP E1) and PCBP2 (hnRNP E2)
(Li et al, 2012) (Fig 5B and C). PCBPs are iron chaperones (Shi et al,
2008; Nandal et al, 2011), found in SGs and P-bodies (Fujimura
et al, 2008, 2009). PCBP2 binds to miRNA precursors and presents
them to DICER for efficient processing (Li et al, 2012). Therefore, the
binding of PCBP1 and 2 to AGO2 and DICER exposes an additional
layer of complexity in the regulation of miRNA biogenesis under
stress.
Finally, AGO2 is phosphorylated by the p38 mitogen-activated
protein kinase on serine-378 under stress (Zeng et al, 2008), consis-
tent with a > 10-fold increase in AGO2 serine-387 phosphorylation
in our system (Fig 5C). Intriguingly, p38 was reported to be persis-
tently activated in ALS (Tortarolo et al, 2003). We further validated
increased interactions of AGO2 with PCBP1, by AGO2 immunopreci-
pitation and Western blot analysis. DICER pull-down was
marginally significant, and we could not validate the increased
interaction of PACT with AGO2 (Fig 5D).
Taken together, these observations point toward substantial
changes in the interactions of DICER and AGO2 with SG compo-
nents. Next, we tested the hypothesis that SG formation may be suf-
ficient to attenuate DICER complex activity. We overexpressed
TIAR, a known initiator of stress granule formation (Kedersha et al,
1999), which reduced DICER catalytic activity in a cell-free assay
(Fig 5E). EIF5A is a translation elongation factor, which is engaged
with SGs under stress (Li et al, 2010) and also with DICER (Fig 5B).
We demonstrated that EIF5A overexpression reduced DICER cata-
lytic activity in a cell-free assay and in cells (Fig 5E and F and
Appendix Fig S6A and B).
Several cellular stress-signaling cascades converge into the phos-
phorylation of Serine-51 of the translation initiation factor 2 alpha
(EIF2A), thereby driving SG formation (Hinnebusch, 2005; Kedersha
et al, 2005). Because EIF2A interactions with AGO2 and/or DICER
increased by stress (Fig 5B and C), we tested the implications of
overexpressing a phosphomimetic version of EIF2A (S51D). Expres-
sion of EIF2A S51D resulted in inhibition of DICER activity (Fig 5G
and Appendix Fig S6C and D), further linking stress signaling to
reduced miRNA biogenesis. Accordingly, phosphorylation-resistant
serine-to-alanine-mutated EIF2A (S51A) (Costa-Mattioli et al, 2007)
enabled a partial recovery from thapsigargin-induced attenuation of
DICER complex activity in mouse embryonic fibroblasts (Appendix
Fig S7 related to Fig 5).
To test whether the experimental manipulations we used are suf-
ficient to induce visible SGs, we utilized immunofluorescence micro-
scopy. This study revealed the onset of TIA1-positive stress granules
with a set of chemical SG inducers, or after transient transfection
with vectors expressing wild-type or mutant forms of FUS, TDP-43
or SOD1. It may be that high plasmid copy number and the stress of
the transient transfection contributed to the induction of SGs by
wild-type FUS, which was not reported in a stably transfected cell
line (Bosco et al, 2010; Dormann et al, 2010; Daigle et al, 2013).
In addition, overexpression of SG proteins that were sufficient
to inhibit DICER activity, EIF5A, EIF2A S51D or TIAR led to the
formation of TIA1-positive SGs (Fig 6). Intriguingly, under all these
conditions, AGO2 was co-localized with TIA1 in SGs, in accordance
with the previous reports that observed AGO2 recruitment into SGs
(Leung et al, 2006; Wu et al, 2011). Therefore, interactions of SG
proteins with AGO2 and/or DICER directly contribute to the attenua-
tion of DICER activity.
We next tested the effect of SGs on DICER activity via chemical
induction or blockade of SG formation (Fig 7A). NSC-34 cells were
treated with puromycin (1 lg/ml, 24 h), which drives dismantling
of translating polysomes, thereby inducing SGs (Blobel & Sabatini,
1971). Puromycin decreased the efficacy of miRNA biogenesis in a
cell-free Dicing assay (Fig 7B) and in cells, as measured by qPCR
(Fig 7C and Appendix Fig S8A and B). Notably, puromycin (1 lg/ml,
24 h) reduced DICER and TRBP levels by 44 and 31%, respectively
(Appendix Fig S9A and B related to Fig 7). Because the interpreta-
tion of the puromycin experiment can take into consideration
reduction in DICER/TRBP levels, we sought a complementary
approach to test whether inhibition of SG formation recovers
miRNA biogenesis from ALS mutant-induced Dicing defects. Cyclo-
heximide (CHX) is known to dissolve pre-formed SGs (Kedersha
et al, 2000). The application of CHX to cultures transfected with
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Figure 5. Stress granule proteins interact with DICER complex components and modulate Dicing activity.
A Diagram depicting the working hypothesis that DICER complex interactions with stress granule proteins is modified by chemical stressors, overexpression of
phosphomimetic EIF2A or overexpression of stress granule proteins.
B, C Targeted mass spectrometry analysis of proteins, co-immunoprecipitated with DICER-FLAG (B) or AGO2-FLAG (C), from HEK293 cells treated with sodium arsenite
(0.5 mM, 60 min). Data are presented as ratio of averaged peptide counts from three different peptide standards per protein, relative to peptide levels in untreated
cells. Note that two peptides were identified above threshold for EIF5A and for TRBP in the AGO2-IP, and AGO2 phospho-S387 is measured by a single peptide. Averages
 s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by two-sided Student’s t-test, between arsenite and control treatment are denoted.
D Western blot study and densitometry of DICER, AGO2, PCBP1 and PACT after AGO2-FLAG immunoprecipitation, in three different biological replicates without or
with sodium arsenite (0.5 mM, 60 min). Averages  s.e.m.; two-sided Student0s t-test, ***P < 0.001, for changes in AGO2 co-immunoprecipitated protein levels.
E In vitro Dicing activity assay in HEK293 cell lysate 72 h post-transfection with EIF5A or TIAR. Averages  s.e.m.; ****P < 0.0001 by two-sided Student’s t-test from
> 3 independent biological replicates.
F, G Inhibition score of individual pre-miRNA:miRNA pairs of HEK293 cells transfected with EIF5A (F) or phosphomimetic form of EIF2A (S51D) (G). Calculated values are
based on qPCR analysis of pre-miRNAs and mature miRNAs of NSC-34 cell RNA, presented in Appendix Fig S6. Inhibition score was normalized to values in cells
transfected with control vector. Averages  s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.001 by two-sided Student’s t-test from > 3 independent biological replicates.
Source data are available online for this figure.
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Figure 6. Localization of AGO2 to TIA1-positive stress granules.
A AGO2-FLAG HEK293 cells were treated with sodium arsenite (0.5 mM, 60 min), paraquat (25 lM, 24 h) or carrier (water), thapsigargin (10 nM, 24 h) or DMSO,
puromycin (1 lg/ml and 2 lg/ml for 24 h) or carrier (water).
B Depicted are micrographs of AGO2-FLAG HEK293 cells transfected with plasmids as indicated and stained with antibodies for FLAG and TIA1, 72 h post-transfection.
C Micrographs of HEK293 cells transfected with plasmids as indicated and stained with antibodies for AGO2 and TIA1, 72 h post-transfection.
Data information: Scale bars indicate 10 lm.
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FUS R495X-, TDP-43 A315T- or SOD1 G93A-expressing vectors was
able to mitigate the reduction in DICER complex activity (Fig 7D–F
and Appendix Fig S8C–H) and reduced the abundance of visible
SG that were quantified by confocal microscopy (Fig 7G and H).
Noteworthy, it is unlikely that the effect of CHX was due to a
general inhibition of protein synthesis since puromycin, which
equally inhibits translation, had an opposite effect (Fig 7B).
Furthermore, with the CHX concentrations we used, we did not
see a reduction in the ectopic expression of FLAG-TDP-43 A315T
or GFP-FUS R495X and CHX was unable to affect miRNA levels
when applied to untransfected NSC-34 cells (Appendix Fig S10A–C,
related to Fig 7).
miRNAs down-regulation in the SOD1 G93A mouse model of ALS
is reversed by enoxacin
We next extended our observations to the SOD1 G93A mouse model
of ALS (B6SJL-Tg (SOD1*G93A)1Gur/J mouse strain) (Gurney et al,
1994). We detected down-regulation of several miRNAs in SOD1
G93A spinal cords at day 137, relative to the expression of the same
miRNAs at day 77. These changes were not observed in age-matched
and litter-matched wild-type controls (Appendix Fig S11A related to
Fig 8). The mRNA and protein levels of AGO2, DICER, PACT and
TRBP remained unchanged (Appendix Fig S11B and C related to
Fig 8). The relatively mild reduction may be due to extracting RNA
from the whole spinal cord tissue.
Recently, enoxacin was shown to increase the expression of
miRNAs in the frontal cortex of rats with beneficial impact on
depression (Smalheiser et al, 2014). Therefore, we tested whether
miRNA levels are changed in vivo after oral application of enoxacin
(n = 5) or carrier (water, n = 5) to SOD1 G93A male sibling-
matched cohorts. Treatment starting on day 42 of the mouse life did
not affect miRNA levels in wild-type motor cortices that
were harvested at day 90, relative to controls. However, the levels
of several miRNAs were up-regulated by enoxacin in SOD1 G93A
motor cortices (Appendix Fig S11D and E related to Fig 8).
Enoxacin therapy is beneficial for neuromuscular function in the
SOD1 G93A mouse model of ALS
We next tested whether enoxacin has a beneficial effect on neuro-
muscular function of SOD1 G93A mice (Gurney et al, 1994). We
observed a ~7-day delay at the onset of neurological symptoms of
the enoxacin-treated group (n = 40) relative to sibling-matched male
cohort treated with carrier (water, n = 37) (Fig 8A). Consistently,
weight peak and onset of weight decline, which is defined by the loss
of 1 g bodyweight after the weight peak, were delayed in enoxacin-
treated mice (Fig 8B and C). Kaplan–Meier survival analysis did not
yield significant differences between the two groups (Fig 8D).
However, evaluation of neurological status by employing a common
neurological scoring system, with numerical values increasing from
0 to 4 as the disease progresses (Gill et al, 2009). Neurological
scoring revealed that the enoxacin-treated cohort was superior to
untreated controls (Fig 8E).
To further evaluate motor function, we performed automated
quantitative gait analysis, using the CatWalk system (Neumann
et al, 2009). Swing speed was significantly higher and stride length
was significantly increased in the enoxacin-treated group, relative to
untreated controls (ten matched siblings per group, Fig 8F and G).
Additionally, the performance of the enoxacin-treated group was
superior to untreated siblings in a rotarod test (n = 25 control,
n = 29 enoxacin, Fig 8H). Therefore, enoxacin has a beneficial
effect on multiple clinical parameters of the SOD1 G93A mouse
model. Furthermore, even a lower enoxacin dose significantly
improved gross strength on a hang-wire assay and the clinical
neurological score, relative to controls (16 animals treated with
enoxacin, 15 untreated controls; Fig 8I and J). Finally, enoxacin-
treated animals (n = 6) moved significantly more than untreated
controls (n = 5) in a fully automated infrared-based home cage
locomotion assay (Fig 8K). Although enoxacin did not extend the
lifespan of the SOD1 G93A model, an array of different assays
revealed improved neuromuscular function, suggesting a beneficial
profile. Noteworthy, riluzole, the only FDA-approved drug for ALS,
lacks survival benefit in SOD1G93A mice (Scott et al, 2008; Li et al,
2013a). Therefore, as previously suggested (Scott et al, 2008), the
predictive value of the aggressive SOD1 G93A model may be limited
due to its 23 transgene copies in testing novel pharmacological
interventions.
We also tested enoxacin in the TDP-43 A315T transgene
(Wegorzewska et al, 2009). Enoxacin-treated TDP-43 A315T
females displayed an improved neurological score, relative to a
control cohort (nine treated animals, eight untreated controls;
treatment started on day 42; Fig 8L), performed better on the Hang-
wire test (Fig 8M) and displayed improved stride length (Fig 8N).
Of note, characterization of the TDP-43 A315T mice was performed
until the onset of clinical gastro-intestinal pathology, which leads to
early death of this TDP-43 A315T mouse line and precludes the full
development of ALS (Esmaeili et al, 2013).
Discussion
miRNAs function at an intriguing interface of cellular stress and
disease (Leung & Sharp, 2007; Mendell & Olson, 2012; Emde &
Hornstein, 2014). Accordingly, facets of miRNA malfunction in
ALS or frontotemporal dementia were reported in the past: We
demonstrated that loss of DICER is sufficient to cause progressive
degeneration of spinal motor neurons (Haramati et al, 2010). In
addition, specific miRNA genes are involved in feedback loops
upstream or downstream of FUS (Morlando et al, 2012; Dini
Modigliani et al, 2014) or TDP-43 (Buratti et al, 2010; Kawahara &
Mieda-Sato, 2012). miRNAs were suggested to regulate neuromus-
cular junction repair (Williams et al, 2009; Valdez et al, 2014), to
plausibly regulate neuro-inflammation in ALS (Koval et al, 2013)
and may serve as circulating biomarkers (De Felice et al, 2014;
reviewed in Droppelmann et al, 2014; Gascon & Gao, 2014).
The current work provides novel evidence that global down-
regulation of miRNAs is a molecular commonality for genetically
unrelated forms of human ALS and suggests that similar previous
observations (Campos-Melo et al, 2013) are primarily due to
changes in miRNA expression in motor neurons.
The observations in human samples led us to investigate the
mechanism. We demonstrated that decreased DICER catalytic activ-
ity is reducing miRNA levels. Several lines of evidence suggest that
DICER complex activity is inhibited by the emergence of SGs:
(i) The interaction of several RNA-binding proteins that are normally
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Figure 7. Stress granule formation impacts on Dicing complex efficacy.
A Diagram depicting the working hypothesis that DICER complex activity is attenuated by stress granules that can be initiated by polysome disassembly. Inhibition of
DICER activity by overexpression of ALS-causing proteins can be mitigated by inhibiting stress granule formation with cycloheximide or by enhancing DICER
activity with enoxacin.
B Dicing in vitro assay was performed on lysates of NSC-34 cells, treated with puromycin (1 lg/ml for 24 h) or carrier (water). Average values of > 4 independent
biological repeats; error bars represent s.e.m.; ***P < 0.001 by two-sided Student’s t-test.
C–F Inhibition score of individual pre-miRNA:miRNA pairs in NSC-34 cells treated with puromycin (1 lg/ml for 24 h) or carrier (water) (C) or cells transfected with ALS-
causing FUS R495X (D), TDP-43 A315T (E) or SOD1 G93A (F) or control vector and treated with low-dose cycloheximide (CHX) (0.02 lg/ml) or carrier (water), starting
at 6 h post-transfection. Cells were harvested 72 h post-transfection. Calculated values are based on qPCR analysis of pre-miRNAs and mature miRNAs presented
in Appendix Fig S8. Inhibition score was normalized to values in cells transfected with control vector. Averages  s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001 by two-sided Student’s t-test from > 3 independent biological replicates.
G AGO2-FLAG HEK293 cells transfected with FUS R495X or SOD1 G93A and HEK293 transfected with TDP-43 A315T vector versus control plasmid treated with
cycloheximide (CHX, 0.02 lg/ml) or carrier and immunostained with antibodies as indicated 72 h post-transfection. Scale bars indicate 10 lm.
H Percentage of HEK293 cells with stress granules overexpressing TDP-43 A315T or FUS R495X in the presence or absence of cycloheximide (0.02 lg/ml for 72 h).
Average was calculated from > 100 cells in > 5 pictures per condition; error bars represent s.e.m; ***P < 0.001 by two-sided Student’s t-test.
Source data are available online for this figure.
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Figure 8. Beneficial impact of enoxacin on neuromuscular function of two different mouse ALS models.
A–H Oral application of enoxacin (800 mg/kg bodyweight/day, n = 40) or carrier (water; n = 37) to SOD1 G93A male mice started on day 42 of the mouse life.
(A) Onset of symptoms (neurological score 1); log-rank Mantel–Cox test, **P = 0.0025. (B) Weight peak, log-rank Mantel–Cox test, ***P = 0.0002. (C) Onset of
weight decline, defined as the loss of 1 g bodyweight after the weight peak were measured; log-rank Mantel–Cox test, **P = 0.0099. (D) Kaplan–Meier survival plot
reveals comparable life span of SOD1 G93A mice, regardless of therapy. Not significant (n.s.), by log-rank Mantel–Cox test. (E) Average neurological score, which
increases with disease progression, per cohort (n = 40 enoxacin-treated, n = 37 controls), two-way ANOVA test, ****P < 0.0001 (control versus enoxacin). Post hoc
Holm–Sidak tests did not reveal significant differences comparing control versus enoxacin at single time points. (F, G) Fully automated gait CatWalk analysis with
ten matched siblings per group. (F) Four-paw swing speed on day 73, two-way ANOVA *P = 0.027 (control versus enoxacin). (G) Four-paw stride length on day 80,
two-way ANOVA *P = 0.012 (control versus enoxacin). Post hoc Holm–Sidak tests did not reveal significant differences when comparing single-paw behavior.
(H) Multiple time point rotarod performance, normalized to initial performance at day 92 of each individual (n = 25 control, n = 29 enoxacin). Two-way ANOVA
with repeated measures for each individual, *P = 0.047 (control versus enoxacin), followed by post hoc Holm–Sidak tests, *P < 0.05, ***P < 0.001, ****P < 0.0001.
I–K Oral application of enoxacin 200 mg/kg bodyweight/day or carrier (water) to SOD1 G93A male mice started day 42 of the mouse life. (I) Hang-wire assay (n = 15
control, n = 16 enoxacin), two-way ANOVA (control versus enoxacin) **P = 0.0027, followed by post hoc Holm–Sidak tests of different time points within groups,
**P < 0.001, ****P < 0.0001. Lower hang-wire score indicate greater strength. (J) Neurological score, which increases with disease progression (n = 15 control,
n = 16 enoxacin), two-way ANOVA (control versus enoxacin) **P = 0.0084, followed by post hoc Holm–Sidak test reveals a significant difference at 20 weeks of age
**P < 0.01. (K) Fully automated infrared-based home cage locomotion analysis (InfraMot, TSE-Systems) at 30-min intervals over a period of 46 h, days 129–130
(n = 5 control, n = 6 enoxacin). Two-way ANOVA (control versus enoxacin), ***P = 0.0004.
L–N Oral application of enoxacin 200 mg/kg bodyweight/day (n = 9) or carrier (water; n = 8) to TDP-43 A315T females started at day 42 of the mouse life. (L) Onset of
symptoms (neurological score 1); two-way ANOVA (control versus enoxacin) **P = 0.0013, followed by post hoc Holm–Sidak tests reveals ***P < 0.001 at day 84.
(M) Hang-wire assay, two-way ANOVA (control versus enoxacin), **P = 0.0079, followed by post hoc Holm–Sidak tests of different time points within groups, with
*P < 0.05. Lower hang-wire scores indicate greater strength. (N) CatWalk analysis revealed better performance, as assessed by four-paw stride length on day 83,
two-way ANOVA (*P = 0.045). Post hoc Holm–Sidak tests did not reveal significances comparing single-paw behavior.
Data information: All error bars, s.e.m. Note that in (A–C, D), x-axis starts at days 60 and 100, respectively. Discontinuation of y-axis in (F, G, N) is marked by oblique
crossing line.
Source data are available online for this figure.
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found in stress granules with DICER or AGO2 increases upon stress.
(ii) Initiating SGs by overexpressing EIF5A or TIAR, the phospho-
mimetic form EIF2A, or by puromycin, was sufficient to reduce
DICER activity in cells and in cell lysates. (iii) AGO2, a cofactor of
DICER, co-localizes with TIA1 in cytoplasmic SGs after transfection
of ALS-causing genes. (iv) Blocking SGs with cycloheximide or
with non-phosphorylatable serine-to-alanine 51 mutant of EIF2A
reversed the negative effect of ALS-causing mutants on miRNA
biogenesis. Puromycin and cycloheximide are two inhibitors of
translation, yet they display opposite effects both on pre-miRNA
processing and, respectively, on SG formation. Thus, the protective
activity of cycloheximide in motor neurons (Yang et al, 2013) is
consistent with its ability to inhibit SG formation and to improve
miRNA biogenesis. (v) These observations are in line with the
previous identification of TDP-43 and FUS in SGs and with the
fact that TDP-43 binds DICER and AGO2 directly (Kawahara &
Mieda-Sato, 2012), providing a conceivable explanation also for the
stronger molecular phenotypes observed with TDP-43 and FUS,
relative to SOD1.
Therefore, we suggest that stress and SG formation initiate
dynamic changes in DICER interactions with its co-factors, in a way
that diminishes DICER complex activity. This may be because of
acquired or lost interactions under stress and may be related to
AGO2 post-translational modifications (Leung et al, 2006; Qi et al,
2008; Zeng et al, 2008; Shen et al, 2013) or to increased AGO2 bind-
ing to DICER, which counter-intuitively decreases DICER activity
(Tahbaz et al, 2004).
Enoxacin increases the binding affinity of TRBP to pre-miRNAs,
thereby augmenting pre-miRNA processing (Shan et al, 2008; Melo
et al, 2011). We demonstrated that impaired miRNA biogenesis is
mitigated by enoxacin with beneficial clinical outcome on the neuro-
muscular performance of two different ALS mouse models. We did
not observe any lifespan extension, but also Riluzole, the only FDA-
approved drug for ALS, lacks survival benefit in SOD1 G93A mice
(Scott et al, 2008; Li et al, 2013a). Therefore, as previously
suggested (Scott et al, 2008), the predictive value of the aggressive
SOD1 G93A model may be limited in testing novel pharmacological
interventions. Furthermore, SOD1 effect on DICER activity may be
more limited than the effects mediated by FUS or TDP-43, which are
RNA-binding proteins that are directly engaged in SGs.
Nonetheless, if DICER and miRNAs are indeed instrumental in
the pathogenesis of ALS in humans, as we suggest, these observa-
tions hold promise for future intervention by validating DICER as a
new therapeutic target. Furthermore, enoxacin is a particularly
intriguing candidate for clinical assessment, based on its established
safety and pharmacokinetic profile and because several forms of
ALS converge in the down-regulation of miRNAs. However, more
effective DICER agonists might exhibit more dramatic beneficial
effects in ALS in the future.
miRNAs impart robustness to cellular programs in development
and in the adult life (Hornstein & Shomron, 2006; Pelaez & Carthew,
2012; Cassidy et al, 2013; Emde & Hornstein, 2014). Accordingly,
even moderate DICER and miRNA insufficiency contributes to failed
homeostatic mechanisms, allowing the activation of myriad aber-
rant pathways that were otherwise repressed under normal miRNA
activity. The consequences may contribute particularly to dimin-
ished stress resistance, creating a vicious cycle, which further
increases neuronal stress up to the threshold of malfunction and
death. Accordingly, in one example, even mild but long-term down-
regulation of brain-enriched miR-124 affected AMPA expression and
frontotemporal dementia phenotype (Gascon et al, 2014).
The sensitivity of DICER activity to cellular stress is not limited
to motor neurons and may be probably relevant to other tissues
under chronic stress, where decrease in miRNA or DICER abun-
dance was reported (Kaneko et al, 2011; Mori et al, 2012; Inukai &
Slack, 2013; Nidadavolu et al, 2013). Thus, evaluating whether
stress impinges on DICER activity in other disease states will be
valuable. The variability in miRNA biogenesis with different stres-
sors or by using different cell types suggests additional factors that
are currently unknown.
In summary, we provide evidence for the control of miRNA
biogenesis at the level of DICER complex activity, by several stress-
related cellular changes. The consecutive reduction in miRNA levels
unifies various forms of ALS, suggesting that the development of
novel therapies might focus on DICER or miRNAs as common criti-
cal effectors of neuronal integrity.
Materials and Methods
Human tissue miRNA analysis
Human nervous tissues were acquired by way of an Investigational
Review Board and Health Insurance Portability and Accountability
Act compliant process. Sporadic ALS nervous systems were from
patients who had met El Escorial criteria for definite ALS. Informed
consent was obtained from all subjects. Tissue measurements were
carried out post-mortem and conformed to the WMA Declaration of
Helsinki and the Department of Health and Human Services
Belmont Report. Sporadic ALS nervous systems were from patients
who had bulbar or arm-onset disease and caudal progression, and
thus, the lumbar regions had relatively abundant residual motor
neurons. Tissue collections were as previously described:
Completed within 4–6 h of death, the motor system was dissected,
embedded in OCT and stored at 80°C. RNA quality was assessed
using microelectrophoresis on an Agilent 2100 Bioanalyzer as previ-
ously described. Microdissected cell punches were captured on
CapSureTM Macro LCM Caps (Arcturus Bioscience). 35 to 50 cryosec-
tions were cut at a thickness of 9 lm in a 18°C cryotome and
placed onto uncharged glass slides. The sections were returned
to 80°C for a minimum of 3 h. They were stained with cresyl
violet acetate in a 10-step, timed, nuclease-free immersion process.
Motor neurons were microdissected using a Pixcell IIe Laser
Capture Microdissection (LCM) System (Arcturus Bioscience) and
CapSureTM Macro LCM Caps (Applied Biosystems). Each LCM
session collected 500–1,000 motor neuron punches and lasted
< 2.5 h. Total RNA was isolated using the RNAqueous Micro kit
(Life Technologies) as per the manufacturer’s procedure. RNA
quality was assessed by spectrophotometric analysis using a Nano-
drop ND-1000 spectrophotometer and an Agilent 2100 Bioanalyzer.
Expression of 667 microRNAs was assessed using the microRNA
TaqMan qPCR Megaplex pools array on an ABI 7900HT Fast Real-
Time PCR System (Life Technologies). Technical replicates were run
after pre-amplification using the manufacturer’s protocol. Relative
quantification was calculated by comparing arithmetic mean of
three small RNA control genes nucleolar RNU48/SNORD48,
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RNU44/SNORD44 and splicosome-related U6. Two-way ANOVA test
was performed with DataAssist Software (Life technologies Inc.).
In situ hybridization was performed on 7-lm sections of frozen
spinal tissue from lumbar regions, briefly fixed in 4% paraformalde-
hyde and incubated in 2 lg/ml proteinase K. Slides were then incu-
bated for 10 min in 0.13 M 1-methylimidazole (Sigma), 300 mM
NaCl, pH 8.0 and further fixed in EDC (Sigma) following Pena et al
(2009), acetylated for 30 min in a solution of freshly prepared 0.1 M
triethanolamine and 0.5% (v/v) acetic anhydride. Hybridization of
sections with 4 pmol of 50 and 30 DIG-labeled miR-9 and miR-124
LNA probes followed manufacturer’s instructions (Exiqon).
Tissue culture vectors and small molecules
HEK293 cells (American Type Culture Collection) and NSC-34 cells
(Cellutions Biosystems Inc.) were cultured in high-glucose DMEM
(Gibco), 1% L-glutamine, 10% fetal calf serum and 1% penicillin/
streptavidin. Mouse embryonic fibroblasts (MEFs) were cultured in
DMEM (Gibco), 15% fetal calf serum, L-glutamine, 1% penicillin/
streptavidin and sodium pyruvate. AGO2-FLAG-expressing HEK293
cells were a gift of Markus Landthaler. EIF2A S51A mouse embry-
onic fibroblasts were provided by Prof. Chaim Kahana, Weizmann
Institute of Science, Israel. Mouse embryonic motor neurons were
harvested as described in Milligan and Gifondorwa (2011). Expres-
sion vectors are as follows: EIF2A 3 (S51D) from David Ron
(Addgene plasmid # 21809); pBabe_puro_DEST_Flag_EIF5A2 from
William Hahn (Addgene plasmid # 45266); and pLJM60-Tiar from
David Sabatini (Addgene plasmid # 38244). Wild-type and R495X
FUS vector were provided by Daryl Bosco (University of Massachu-
setts, Boston), wild-type and A315T TDP-43 vectors by Markus
Landthaler (MDC Berlin, Germany), and wild-type and G93A SOD1
vectors by Yoram Groner (WIS, Israel). DICER-FLAG and AGO2-
FLAG plasmids were kindly provided by Narry Kim (Seoul National
University, South Korea). Enoxacin was supplied by Sigma-Aldrich
(E3764-5G) or Buckton-Scott (Germany). Thapsigargin, paraquat,
cycloheximide and puromycin are purchased from Sigma-Aldrich,
Israel.
RNA analysis
RNA was extracted using Tri reagent (Molecular Research Center
Inc.) or Qiazol with consecutive use of the miRNeasy Mini Kit (Qia-
gen). Pre-miRNA and miRNA reverse transcription was performed
using miScript Kits No. I & II (Qiagen). Quantitative analysis of
miRNA and pre-miRNA expression was performed in > 3 indepen-
dent biological repeats and additionally in technical duplicates with
StepOnePlus quantitative Real-Time PCR System, and two-way
ANOVA test was performed with DataAssist Software (Life technolo-
gies Inc.). Primers are described in Table EV1 and additional pre-
miRNA sequences are from Jiang et al (2005).
Cell-free dicing assay
Dicing assay is described in Melo and Melo (2014) with the follow-
ing modifications: dsRNA substrate for measuring DICER activity
was annealed from 50Phos/mCmU rCmArU mUrUrC rCrUrG
mGrUmA rUmGrA mCrArA rCrGrA mAmU/30IABkFQ and 50Cy3/
mAmU mUrCrG rUrUrG mUrCmA rUmArC rCrArG rGrArA rArUmG
rAmGmC rU (Integrated DNA Technologies). Cells were lysed via
sonication in hypotonic solution, with consecutive DICER assay
reaction assembly by mixing 3 ll of 10× Buffer K (200 mM Hepes–
KOH, pH 7.0, 20 mM dithiothreitol (DTT), 20 mM MgCl2); 3 ll of
10 mM ATP; 1.5 ll of 0.5 M, freshly dissolved, creatine phosphate;
0.9 ll of 1 mg/ml creatine phosphate kinase; 0.6 ll of ribonuclease
inhibitor (40 units/ll); 3 ll of labeled dsRNA (50 nM); and 18 ll of
cell extract. DICER assay mix was incubated at 30°C for 2 h and
diluted with 100 ll of ultra-pure water, and then, 10 ll was trans-
ferred to 384-multiwell plate (10 technical repeats for each reaction)
and measured on PHERAstar FS microplate reader (BMG Labtech).
Pre-annealed ssRNA Cy3 fluorescent oligo served as positive control
for calibration curve. Annealed and quenched dsRNA without cell
extract served as negative control for quantification of background
fluorescence.
Western blot analysis
Cell extracts or immune-purified proteins were eluted by boiling in
X5 sample buffer (60 mM Tris–HCl pH 6.8, 25% glycerol, 2% SDS,
14.4 mM b-mercaptoethanol, 0.1% bromophenol blue) for 5 min.
The samples were separated via 8% SDS–polyacrylamide gel elec-
trophoresis at 120 V for 70 min, electro-transferred onto nitrocellu-
lose membrane (Whatmann, 10401383) at 100 V for 1 h, stained
with Ponceau (Sigma, P7170) to asses transfer quality and then
blocked for 1 h at room temperature with 5% milk protein in PBS +
0.05% Tween-20 (0.05% PBST). Blocked membranes were then
incubated with shaking at 4°C overnight with primary antibodies in
5% bovine serum albumin, 0.02% sodium azide and five drops of
phenol red in 0.05% PBST. Membranes were next washed 3 times
for 5 min at room temperature with 0.05% PBST and then incu-
bated with horseradish peroxidase-conjugated species-specific
secondary antibodies in 5% milk for 1 h at room temperature.
Membranes were washed three times for 5 min in 0.05% PBST and
visualized by ImageQuantTM LAS 4000 (GE Healthcare Life Sciences)
using EZ-ECL Chemiluminescence detection kit (Biological Indus-
tries, 20-500-120). Primary antibodies used are as follows: anti-
DICER (ab13502) 1:500; anti-AGO2 (ab32381) 1:500; anti-PACT
(ab75749) 1:1,000; anti-TRBP (ab42018) 1:1,000; anti-PCBP1
(ab74793) 1:1,000 from Abcam; anti-GAPDH (Ambion, AM4300)
1:4,000; anti-phospho-eIF2a (Ser51) (Cat# 04-342EMD, Millipore)
1:500; anti-eIF2a (sc-11386, Santa Cruz Biotechnology) 1:200; anti-
TLS/FUS (cat. 611385, BD Transduction Laboratories) 1:500; and
anti-TDP-43 (10782-2-AP, Proteintech) 1:1,000.
Mass spectrometry
For mass spectrometry, HEK293 cells that stably express AGO2-FLAG
(n = 3 for each group) or DICER-FLAG-transfected cells (48 h post-
transfection, n = 4 for each group) were untreated or stressed with
0.5 mM sodium arsenite for 60 min before harvest. IP was performed
with the FLAG-IPT1 Kit (Sigma-Aldrich). Negative controls were
HEK293 cells not containing a FLAG construct. Eluted proteins and
the FLAG peptide were filtered using 3-kDa molecular weight cutoff
spin columns (Amicon, Millipore). Buffer was exchanged to 50 mM
ammonium bicarbonate (Sigma-Aldrich) in the same step. Proteins
were reduced by addition of dithiothreitol (Sigma-Aldrich) to a final
concentration of 5 mM and incubation for 30 min at 60°C and
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alkylated with 10 mM iodoacetamide (Sigma-Aldrich) in the dark for
30 min at 21°C. The proteins were then digested using trypsin
(Promega; Madison, WI, USA) at a ratio of 1:50 (w/w trypsin/
protein) for 16 h at 37°C. Digestion was stopped by addition of 1%
trifluoroacetic acid (TFA). Samples were stored in 80°C until analy-
sis. Each sample was spiked with the mixture of 51 heavy isotopically
labeled peptides (JPT Technologies). Heavy labels included U-13C6;
U-15N4 for peptides terminating with Arg and U-
13C6; U-
15N2 for Lys.
ULC/MS grade solvents were used for all chromatographic steps.
Each sample was loaded using split-less nano-ultra-performance
liquid chromatography (10k psi nanoAcquity; Waters, Milford, MA,
USA). Mobile phase was as follows: A) H2O + 0.1% formic acid and
B) acetonitrile + 0.1% formic acid. Desalting of samples was
performed online using a reverse-phase C18 trapping column
(180 lm i.d., 20 mm length, 5 lm particle size; Waters). The
peptides in samples were separated using a C18 T3 HSS nano-column
(75 lm i.d., 250 mm length, 1.8 lm particle size; Waters) at 0.3 ll/
min. Peptides were eluted from the column and into the mass spec-
trometer using the following gradient: 3–30% B in 90 min, 30–35%
in 10 min, 35–90% B in 5 min, maintained at 90% for 5 min and
then back to initial conditions. The analytical column was coupled
with a quadruple orbitrap mass spectrometer (Q Exactive, Thermo
Scientific), via a nano-ESI interface. Parallel reaction monitoring of
mass spectrometry (MS) was according to Peterson et al (2012) at
maximum injection time of 300 ms, resolution of 35,000 and target
automatic gain control (AGC) of 2e5. Samples were analyzed in a
random order, measuring the light and heavy forms of each target
peptide. Data were processed with Skyline software (MacLean et al,
2010). Extracted ion chromatograms were integrated, and the ratio of
the light to heavy forms was calculated. Student’s t-test was used,
after logarithmic transformation, for statistical calculations of the
differential peptide expression. Peptide sequences for mass
spectrometry are described in Table EV1.
Immunocytofluorescence microscopy
Wild-type or stably transfected AGO2-FLAG HEK293 cells were
cultured on poly-A-lysin-coated coverslips and further subjected to
transfection or treated with stress-inducing chemicals. For micro-
scopy, cells on coverslips were rinsed with PBS, fixed with 4%
formaldehyde, permeabilized with 0.1% Triton X-100 (Sigma-
Aldrich, St. Louis, MO), blocked with PBS, 2% BSA and incubated
with anti-TIA1 antibody (sc-1757, Santa Cruz Biotechnology), anti-
Flag antibody (F1804, Sigma-Aldrich) and anti-AGO2 (ab32381,
Abcam) overnight. Coverslips were washed three times with PBS
and incubated with secondary antibodies (Cy2 donkey anti-goat
705-495-147 and Cy5 donkey anti-mouse 715-175-150, Jackson
Immunoresearch) for 1 h. Coverslips were washed 3 times with
PBS, mounted with FluoroshieldTM with DAPI (F6057, Sigma) and
captured with a LSM 710 confocal microscope (Carl Zeiss AG).
In vivo enoxacin study
All experiments were performed according to Weizmann Institute of
Science guidelines and IACUC approval (protocol No. 03040512-1).
Mice, B6SJL-Tg(SOD1*G93A)1Gur/J, which were first reported in
Gurney et al (1994), carry a hemizygous high transgene copy
number of the SOD1 G93A mutant on a B6SJL hybrid background
(Jackson Laboratories, 002726). The TDP-43 A315T mouse line
(Wegorzewska et al, 2009) was on a C57BL/6J background (Jack-
son Laboratories, 010700). All experiments were performed sibling-
matched, except the mice in the 200 mg/kg bodyweight SOD1
G93A enoxacin group, in which mice were randomly assigned to
treatment groups. Animals were group-housed on a 12-h light–dark
cycle. Food and water were provided ad libitum. Food pellets at
cage floor, long sipper tubes on bottles and nutrient gel were used
to ease accessibility to nutrition when mice deteriorated according
to Gill et al (2009). RotaRodTM performance (San Diego Instruments)
was evaluated at ramp speed 4, 40 rpm. Data are presented as the
average latency to fall off the rotarod of three independent rounds
per time point and are normalized to average initial performance at
pre-symptomatic stage for each individual for each time point. A
fully automated gait analysis with the CatWalk XTTM (Noldus)
system was performed. Data were obtained of > 4 independent
rounds on the apparatus. For hang-wire muscle strength assess-
ment, mice were allowed forelimb grip onto a 2-mm-thick horizon-
tal metal wire, suspended 80 cm above surface. Ability to
successfully raise hindlimbs to grip the wire and crawling to the
end of the wire was scored: 1 = successful four-paw grip and crawl-
ing to the end of the wire within < 60 s; 2 = four-paw grip for
> 15 s without crawling; 3 = failure to successfully establish
hindlimb grip in 60 s; and 4 = inability to sustain forelimb grip for
60 s. Each mouse was evaluated in two sessions on two consecu-
tive days, consisting of three trials each, with a 15-min inter-trial
interval. The second day was used to obtain the data as displayed.
Neurological score was assessed according to Gill et al (2009):
0 = > 2 s extension of hindlimbs away from lateral midline when
mouse is suspended by its tail 2–3 times; 1 = collapse or partial leg
collapse toward midline or hind leg trembling during tail suspen-
sion; 2 = toes curl under at least twice during a 12-inch walk, or
any part of foot is dragging along cage/table bottom; 3 = rigid
paralysis or minimal joint movement, foot not being used for
forward motion; and 4 = humane endpoint, mouse cannot right
itself within 30 s on either side. The locomotion of animals was
quantified over a period of 46 h in the home cage, by automated
sensing of body-heat image using an InfraMot (TSE-Systems).
Individual animal movements were summed up every 30 min.
Animal statistics: rotarod performance was evaluated using the
two-way ANOVA with repeated measures for each individual and
post hoc Sidak–Holm tests. Weight peak, weight decline, onset of
symptoms and survival were calculated with log-rank (Mantel–Cox)
test. All other tests employed two-way ANOVA with post hoc
Sidak–Holm tests. All animal statistics were calculated with
GraphPad Prism 6 statistics program.
Expanded View for this article is available online:
http://emboj.embopress.org
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